<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04890353</url>
  </required_header>
  <id_info>
    <org_study_id>haojunwei4</org_study_id>
    <nct_id>NCT04890353</nct_id>
  </id_info>
  <brief_title>Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke</brief_title>
  <official_title>Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conduct this study to investigate whether oral administration of Dimethyl&#xD;
      Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and&#xD;
      effective in in alleviating neurologic deficits in patients with Acute Ischemic Stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>day 7</time_frame>
    <description>The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lesion Volume</measure>
    <time_frame>day 7</time_frame>
    <description>Measured by MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Modified Rankin Scale (mRS)</measure>
    <time_frame>day1</time_frame>
    <description>The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Modified Rankin Scale (mRS)</measure>
    <time_frame>day3</time_frame>
    <description>The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Modified Rankin Scale (mRS)</measure>
    <time_frame>day7</time_frame>
    <description>The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Modified Rankin Scale (mRS)</measure>
    <time_frame>day14</time_frame>
    <description>The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Modified Rankin Scale (mRS)</measure>
    <time_frame>day90</time_frame>
    <description>The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>day 1</time_frame>
    <description>The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>day 3</time_frame>
    <description>The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>day 14</time_frame>
    <description>The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>day 90</time_frame>
    <description>The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Volume</measure>
    <time_frame>day 1</time_frame>
    <description>Measured by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Volume</measure>
    <time_frame>day 3</time_frame>
    <description>Measured by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Volume</measure>
    <time_frame>day 90</time_frame>
    <description>Measured by MRI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>standard management plus Dimethyl Fumarate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>standard management plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimethyl fumarate</intervention_name>
    <description>Dimethyl fumarate 240mg orally twice daily for 3 consecutive days</description>
    <arm_group_label>standard management plus Dimethyl Fumarate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 240mg orally twice daily for 3 consecutive days</description>
    <arm_group_label>standard management plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. &gt;18 y of age;&#xD;
&#xD;
          2. acute onset of focal neurological deficit consistent with acute ischemic stroke;&#xD;
&#xD;
          3. measurable neurological deficit (NIHSS â‰¥ 5);&#xD;
&#xD;
          4. anterior-circulation ischemic stroke defined by magnetic resonance angiography (MRA)&#xD;
             and Diffusion-Weighted Imaging(DWI);&#xD;
&#xD;
          5. onset of symptom to admission more than 4.5 h and less than 72 h. Patients who arrived&#xD;
             within 0-4.5 h poststroke were treated with other medications according to the best&#xD;
             accepted medical treatment guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other diseases of the central nervous system&#xD;
&#xD;
          2. There has been neurological disability in the past (mRS score&gt;2)&#xD;
&#xD;
          3. Difficulty swallowing&#xD;
&#xD;
          4. Arrhythmia, atrioventricular block&#xD;
&#xD;
          5. Use of anti-tumor drugs, other immunosuppressive and immunomodulatory drugs&#xD;
&#xD;
          6. Macular edema&#xD;
&#xD;
          7. MRA shows vertebral basilar artery obstruction&#xD;
&#xD;
          8. Hemorrhagic stroke&#xD;
&#xD;
          9. Patients who are known to have hypersensitivity to dimethyl fumarate or any excipients&#xD;
             of this product&#xD;
&#xD;
         10. Pregnant and lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dimethyl Fumarate</keyword>
  <keyword>acute ischemic stroke</keyword>
  <keyword>immune modulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

